Primer Offered For Scientists Bringing Drugs To Market

FASEB speakers teach scientists about drug development and urge researchers to shape the regulatory process WASHINGTON--Biochemists isolating novel chemical compounds could use a bit more street smarts if they want to raise the profile - and budgets - of their research, according to university and industry scientists attending this month's annual meeting of the Federation of American Societies for Experimental Biology. Speaking at a symposium on the "Impact of Federal Agencies on Drug Develop

Written byDiana Morgan

| 3 min read

Save for Later

Listen with Speechify

0:00

3:00

FASEB speakers teach scientists about drug development and urge researchers to shape the regulatory process

WASHINGTON--Biochemists isolating novel chemical compounds could use a bit more street smarts if they want to raise the profile - and budgets - of their research, according to university and industry scientists attending this month's annual meeting of the Federation of American Societies for Experimental Biology.

Speaking at a symposium on the "Impact of Federal Agencies on Drug Development," the scientists tried to bring other researchers up to speed on the Byzantine and often dilatory process of drug development. And they warned that understanding how Congress and the federal government works - especially getting a grip on the requirements for Food and Drug Administration (FDA) approval - can be even more confusing.

Scientists doing basic research tend to be hobbled by their ignorance of the world outside the laboratory door, said panelist Darrell R. Abernethy, ...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!

Join for free today

Already a member? Login Here